110 related articles for article (PubMed ID: 14675982)
1. Comparative analysis of oestrogen and raloxifene effects on the phospholipid composition of high density lipoproteins in healthy postmenopausal women.
Piperi C; Kalofoutis C; Papapanagiotou A; Skenderi C; Kalofoutis A
J Obstet Gynaecol; 2004 Jan; 24(1):52-7. PubMed ID: 14675982
[TBL] [Abstract][Full Text] [Related]
2. Effects of hormone replacement therapy on the phospholipid composition of high density lipoproteins in postmenopausal women.
Papapanagiotou A; Koufali MM; Zachari A; Charalabidou C; Kalofoutis A
J Obstet Gynaecol; 2001 Jan; 21(1):56-61. PubMed ID: 12521913
[TBL] [Abstract][Full Text] [Related]
3. Beneficial effects of raloxifene and atorvastatin on serum lipids and HDL phospholipids levels of postmenopausal women.
Piperi C; Kalofoutis C; Skenderi K; Economidou O; Kalofoutis A
J Obstet Gynaecol; 2004 Jun; 24(4):414-9. PubMed ID: 15203583
[TBL] [Abstract][Full Text] [Related]
4. Effects of conjugated equine estrogens or raloxifene on lipid profile, coagulation and fibrinolysis factors in postmenopausal women.
Dias AR; Melo RN; Gebara OC; D'Amico EA; Nussbacher A; Halbe HW; Pinotti JA
Climacteric; 2005 Mar; 8(1):63-70. PubMed ID: 15804733
[TBL] [Abstract][Full Text] [Related]
5. Effects of raloxifene treatment on the phenotype of blood monocytes.
Boudjeltia KZ; Durez P; Oberweis D; Guillaume M; Remacle C; Cauchie P; Vanhaeverbeek M; Brohée D; Ducobu J; Gregoir C
Can J Physiol Pharmacol; 2010 May; 88(5):601-5. PubMed ID: 20555430
[TBL] [Abstract][Full Text] [Related]
6. Effects of estrogen, raloxifene, and hormone replacement therapy on serum C-reactive protein and homocysteine levels.
Gol M; Akan P; Dogan E; Karas C; Saygili U; Posaci C
Maturitas; 2006 Feb; 53(3):252-9. PubMed ID: 15990257
[TBL] [Abstract][Full Text] [Related]
7. Serum leptin levels and body composition in postmenopausal women treated with tibolone and raloxifene.
Tommaselli GA; Di Carlo C; Di Spiezio Sardo A; Bifulco G; Cirillo D; Guida M; Capasso R; Nappi C
Menopause; 2006; 13(4):660-8. PubMed ID: 16837888
[TBL] [Abstract][Full Text] [Related]
8. Influence of the selective oestrogen receptor modulator (raloxifene hydrochloride) on IL-6, TNF-alpha, TGF-beta1 and bone turnover markers in the treatment of postmenopausal osteoporosis.
Ozmen B; Kirmaz C; Aydin K; Kafesciler SO; Guclu F; Hekimsoy Z
Eur Cytokine Netw; 2007 Sep; 18(3):148-53. PubMed ID: 17823083
[TBL] [Abstract][Full Text] [Related]
9. Effect of long-term treatment with raloxifene on mammary density in postmenopausal women.
Lasco A; Gaudio A; Morini E; Morabito N; Nicita-Mauro C; Catalano A; Denuzzo G; Sansotta C; Xourafa A; Macrì I; Frisina N
Menopause; 2006; 13(5):787-92. PubMed ID: 16912660
[TBL] [Abstract][Full Text] [Related]
10. Predictors of hot flushes in postmenopausal women who receive raloxifene therapy.
Aldrighi JM; Quail DC; Levy-Frebault J; Aguas F; Kosian K; Garrido L; Bosio-Le Goux B; Saráchaga M; Graebe A; Niño AJ; Nickelsen T
Am J Obstet Gynecol; 2004 Dec; 191(6):1979-88. PubMed ID: 15592280
[TBL] [Abstract][Full Text] [Related]
11. Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene.
McClung MR; Siris E; Cummings S; Bolognese M; Ettinger M; Moffett A; Emkey R; Day W; Somayaji V; Lee A
Menopause; 2006; 13(3):377-86. PubMed ID: 16735934
[TBL] [Abstract][Full Text] [Related]
12. Transition from estrogen-progestin to raloxifene in postmenopausal women: effect on vasomotor symptoms.
Gordon S; Walsh BW; Ciaccia AV; Siddhanti S; Rosen AS; Plouffe L
Obstet Gynecol; 2004 Feb; 103(2):267-73. PubMed ID: 14754694
[TBL] [Abstract][Full Text] [Related]
13. [Effects of estrogens and progestogens on the lipid profile in postmenopausal hypogonadism].
García L; Hernández I; Cervera Aguilar R; Ayala AR
Ginecol Obstet Mex; 2001 Sep; 69():351-4. PubMed ID: 11816532
[TBL] [Abstract][Full Text] [Related]
14. Effects of intranasal 17beta-estradiol and raloxifene on lipid profile and fibrinogen in hypercholesterolemic postmenopausal women: a randomized, placebo-controlled clinical trial.
Engin-Ustün Y; Ustün Y; Meydanli MM; Kafkasli A
Gynecol Endocrinol; 2006 Dec; 22(12):676-9. PubMed ID: 17162709
[TBL] [Abstract][Full Text] [Related]
15. The effects of combined raloxifene and oral estrogen on vasomotor symptoms and endometrial safety.
Stovall DW; Utian WH; Gass ML; Qu Y; Muram D; Wong M; Plouffe L
Menopause; 2007; 14(3 Pt 1):510-7. PubMed ID: 17314736
[TBL] [Abstract][Full Text] [Related]
16. A comparison of raloxifene and calcium plus vitamin D on vaginal atrophy after discontinuation of long-standing postmenopausal hormone therapy in osteoporotic women. A randomized, masked-evaluator, one-year, prospective study.
Checa MA; Garrido A; Prat M; Conangla M; Rueda C; Carreras R
Maturitas; 2005 Sep; 52(1):70-7. PubMed ID: 16143228
[TBL] [Abstract][Full Text] [Related]
17. Effect of HMR 3339, a novel selective estrogen receptor modulator, on C-reactive protein levels in healthy postmenopausal women.
Vogelvang TE; Mijatovic V; Kenemans P; Schalkwijk CG; van der Mooren MJ
Am J Cardiol; 2004 Nov; 94(9):1205-8. PubMed ID: 15518626
[TBL] [Abstract][Full Text] [Related]
18. Evidence of improved serum fatty acid profile of postmenopausal women receiving atorvastatin and raloxifene.
Piperi C; Zisaki K; Skenderi K; Kalofoutis C; Kalofoutis A
J Obstet Gynaecol; 2005 Jul; 25(5):476-81. PubMed ID: 16183584
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic dosages of raloxifene do not modify myeloperoxidase and F2alpha-isoprostane levels in postmenopausal women.
Oviedo PJ; Hermenegildo C; Tarín JJ; Cano A
Fertil Steril; 2005 Dec; 84(6):1789-92. PubMed ID: 16359994
[TBL] [Abstract][Full Text] [Related]
20. Effect of raloxifene on the incidence of invasive breast cancer in postmenopausal women with osteoporosis categorized by breast cancer risk.
Lippman ME; Cummings SR; Disch DP; Mershon JL; Dowsett SA; Cauley JA; Martino S
Clin Cancer Res; 2006 Sep; 12(17):5242-7. PubMed ID: 16951244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
